---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-014394"
form_type: "8-K"
ticker: null
cik: "0001603207"
company_name: "Notable Labs, Ltd."
filed_at: "2024-04-12T23:59:59+00:00"
generated_at: "2026-06-03T23:23:24.886294+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Notable Labs reports FY2023 net loss of $11.3M; cash of $8.2M as of Apr 1, 2024

## Summary
- Net loss $11.3M ($3.41 per share) vs $14.4M in 2022; revenue $0.3M from diagnostic services.
- Cash and equivalents $11.8M at Dec 31, 2023; $8.2M as of Apr 1, 2024; runway into Q4 2024.
- R&D expenses fell to $4.7M from $7.8M; G&A rose to $10.1M from $5.2M due to merger costs.
- Phase 2 volasertib/PPMP trial for r/r AML to start in coming months with dose-optimization lead-in.
- Company became public via reverse merger in October 2023; shares outstanding ~9.0M as of Apr 1.

## SEC filing metadata
- accession: 0001493152-24-014394
- form_type: 8-K
- cik: 0001603207
- company_name: Notable Labs, Ltd.
- filed_at: 2024-04-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1603207/000149315224014394/0001493152-24-014394-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1603207/000149315224014394/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-014394
- JSON: https://secwatch.observer/filing/0001493152-24-014394.json
- Plain text: https://secwatch.observer/filing/0001493152-24-014394.txt

## Key facts
- Earnings Releases
  Notable Labs, Ltd. reported the year ended December 31, 2023 results: revenue $0.3 million, net income $(11.3) million, EPS $(3.41) per share.
  - Period: the year ended December 31, 2023
  - Revenue: $0.3 million
  - Net income: $(11.3) million
  - EPS: $(3.41) per share
  - Result: reported results
  source text: Total net revenue includes revenue from diagnostic services performed on a limited basis as an outsourced provider. Total net revenue for the year ended December 31, 2023 was $0.3 million. Total cost of services relate to the costs of processing diagnostic tests of laboratory samples. Total cost of services for the year ended December 31, 2023 was $0.2 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1603207/000149315224014394/0001493152-24-014394-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.